The year 2024 marked an important milestone for Swixx Biopharma. As we celebrated our 10th anniversary, we also introduced our ESG framework, developed through extensive stakeholder engagement. The framework reflects our responsible, compliant, sustainable, and ethical approach to business and defines five ESG building blocks aligned with the UN Sustainable Development Goals:
Building on this foundation, in 2025 we are proud to publish our first comprehensive ESG Report for 2024, which translates our commitments into concrete KPIs and demonstrates measurable progress. This report reflects not only what we have achieved but also our vision for the future: creating lasting value for patients, employees, communities, and the environment.
2024 ESG Highlights
Our ESG Journey
At Swixx Biopharma, sustainability is not a box to check but a continuous journey. The ESG framework provides the vision and direction, and our first ESG report demonstrates our progress with clarity and accountability.
We are guided by the belief that responsible business and lasting impact go hand in hand — and we will continue to improve lives ethically and sustainably, with unwavering dedication. Conscious of global efforts to integrate ESG into our business, we are dedicated to making a positive impact for our partners, patients, and communities.


At the beginning of 2026, Swixx Biopharma is proud to announce that it has become became a “We Support” Endorser of the United Nations Global Compact, the world’s largest corporate sustainability initiative.
This milestone marks a natural extension of Swixx Biopharma’s ESG framework and long-term commitment to responsible business practices. By supporting the UN Global Compact, the company reinforces its alignment with globally recognized standards and the principles that guide its operations across all markets.
The United Nations Global Compact calls on companies to align their strategies and operations with the Ten Principles, covering human rights, labour, environment and anti-corruption. These principles closely reflect Swixx Biopharma’s ESG priorities and its approach to ethical, transparent and sustainable business.
Launched in 2000, the United Nations Global Compact brings together more than 20,000 companies across over 160 countries, working toward a more sustainable, inclusive and responsible global economy.
By becoming a “We Support” Endorser, Swixx Biopharma is further strengthening its ESG commitments by:
“Becoming a ‘We Support’ Endorser of the UN Global Compact is a natural step in our ESG journey. It reinforces our commitment to responsible business practices and to creating meaningful and sustainable impact across the markets we serve,” said Barbara Kosir, Board Member.
Becoming an endorser is not just a milestone, it is a continuation of Swixx Biopharma’s journey to create meaningful and lasting impact.
About the United Nations Global Compact
The United Nations Global Compact is the world’s largest corporate sustainability initiative, calling on companies to align their strategies and operations with ten universal principles and to take actions that advance societal goals, including the Sustainable Development Goals (SDGs).
At the beginning of 2026, Swixx Biopharma became a “We Support” Endorser of the United Nations Global Compact, the world’s largest corporate sustainability initiative.
Swixx Biopharma AG
Neuhofstrasse 5A
CH-6340 Baar
Switzerland
Tel. +41 41 5523 440
info@swixxbiopharma.com
Hybernská 5, 11000 Praha 1
Czech Republic
Tel. +420 242 434 242
info@swixxbiopharma.com